Filter By Category
Archives
Share on -
BIMIRALISIB
Generic Name: BIMIRALISIB
ABSTRACT -
Bimiralisib is a Small molecule kinase-pathway inhibitor. It is generally described as a PI3K/mTOR pathway inhibitor.
Verified structural identifier information used for this sheet includes molecular formula C17H20F3N7O2, PubChem CID 58507717. For regulatory filing, confirm final salt form, stereochemistry, hydration state, and manufacturer-specific specification before submission.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved label, clinical protocol, or specialist direction.
- Dose strength, route, frequency, and duration depend on indication, formulation, renal/hepatic status, and concomitant therapy.
- Do not substitute salt forms, investigational forms, or combination products without formal product review.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Headache, dizziness, nausea, fatigue, rash, or gastrointestinal discomfort
- Laboratory abnormalities may occur depending on mechanism and indication
- Class-specific organ toxicity should be monitored according to the product label or protocol
- Serious hypersensitivity reactions are uncommon but possible.
ALLERGIC REACTIONS -
Hypersensitivity to Bimiralisib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Bimiralisib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Bimiralisib may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- CYP enzyme inhibitors or inducers may alter exposure for many small molecules.
- Transporter interactions may affect absorption, distribution, or elimination.
- Additive pharmacodynamic effects may occur with medicines affecting the same pathway.
- Patients should disclose prescription medicines, over-the-counter medicines, vaccines, herbal products, and supplements.
PREAUTONS–
- Confirm identity, formulation, strength, route, and intended indication before use.
- Review allergy history and prior serious adverse reactions.
- Assess renal/hepatic function and clinically relevant laboratory values when applicable.
- Pregnancy, lactation, pediatric, and geriatric use should follow label or protocol guidance.
WARNINGS –
- This document is for structured API information only and is not a prescribing guide.
- Use only according to approved labeling, clinical-trial protocol, or qualified specialist instruction.
- Stop use and seek urgent medical care for severe allergic reaction, breathing difficulty, collapse, or serious unexpected symptoms.
- Keep out of reach of children.
Share on -
. Developed by